金河生物相关负责人对《证券日报》记者表示："我公司将以此次商誉减值后的资产优化为契机，轻装 上阵、聚焦核心、多元发力，持续夯实核心竞争力并加速培育新增长极。" 1月30日晚间，金河生物（002688）科技股份有限公司(以下简称"金河生物")发布2025年业绩预告，预 计2025年归属于上市公司股东的净利润为3000万元—4200万元。 2025年，金河生物兽用化学药品板块销售持续向好，主要产品金霉素内外销市场销量齐增，特别是海外 市场销量继续增长。该公司六期工程项目投产后，产量增加，保障了国内外市场供货需求，创造了更多 利润。环保服务板块营业收入继续增加，持续提供较多的业绩贡献。 金河生物同步披露计提商誉减值准备的公告显示，经初步减值测试，2025年度累计拟计提商誉减值准备 将影响2025年度公司合并报表归属于上市公司股东的净利润减少约1.5亿元。依此计算，若不考虑商誉 减值准备，2025年该公司预计实现归母净利润1.8亿元至1.92亿元，主营业务展现出较强的韧性与持续发 展能力。 目前，金河生物兽用疫苗板块呈现成熟产品稳增、新品加速兑现的格局。截至目前，金河生物上市销售 的疫苗产品有16个，其中蓝耳灭活疫苗 ...

智通财经APP获悉，华创证券发布研报称，虽然24年Q2开始，行业内卷的扩散对动保企业造成了不小 的冲击，但从供给角度看，持续恶化的内卷局面，客观上已经造成一批企业在出清的路上，25年以来该 行看到兽药原料药价格的企稳回升，其中大环内酯类产品甚至迎来了比较大幅的价格和盈利修复，也看 到多数疫苗品种批签发的同比改善。在此过程中，企业业绩也呈现出明显的分化，但表现好的企业都具 备同一个特质即创新，无论是产品的创新、营销手段的创新还是资本运作的创新，最后在利润表上都有 直观的呈现，值得给予持续重点关注。 华创证券主要观点如下： 疫苗批签发：25年多数疫苗品种批签发均同比增长，新型疫苗表现更胜一筹 根据中国兽药基础数据库，从1-12月全年累计批签发数据来看，多数疫苗品种均同比增长，具体来看， 其中猪用疫苗方面，口蹄疫疫苗、圆环疫苗、伪狂犬疫苗、猪瘟疫苗、胃腹二联疫苗、猪乙脑疫苗分别 同比+6.4%、+13.0%、+5.1%、+11.7%、+21.3%、+7.9%，仅蓝耳疫苗、猪细小疫苗分别同 比-3.7%、-4.5%;禽用疫苗方面，禽流感三价苗、新城疫疫苗、鸭传染性浆膜炎疫苗分别同比+22.8%、 +8.8%、+17. ...

Core Viewpoint - TianKang Pharmaceutical Co., Ltd. continues to face declining performance in the first three quarters of the year, with high accounts receivable and low capacity utilization, raising concerns from regulatory authorities regarding its expansion plans [1] Financial Performance - Revenue and net profit have declined for two consecutive years, with revenues of 1 billion yuan, 1.055 billion yuan, and 1.052 billion yuan from 2022 to 2024, and net profits of 204 million yuan, 165 million yuan, and 153 million yuan during the same period, reflecting year-on-year declines of 18.36% and 11.20% respectively [3] - For the first nine months of 2025, the company reported a year-on-year revenue decline of 20.49% and a net profit decline of 42.44%, while comparable companies in the industry saw average revenue growth of 1.60% and net profit growth of 49.06% [4] Accounts Receivable - The company's accounts receivable at the end of the reporting periods were 338 million yuan, 377 million yuan, and 364 million yuan, accounting for 10.40%, 10.70%, and 10.95% of total assets respectively [7] - As of June 2025, accounts receivable stood at 482 million yuan, with 72.32% from government procurement clients, and overdue amounts from direct sales and distribution clients totaling 42.81 million yuan [7] Capacity Utilization and Expansion Plans - The company plans to raise 527 million yuan for various projects, including 128 million yuan for the expansion of veterinary vaccine production and 105 million yuan for the renovation of brucellosis vaccine production [9] - The current production capacity for brucellosis vaccine is 150 million doses, with capacity utilization rates of 36.02%, 43.72%, 44.44%, and 34.61% over the reporting period [11] - Regulatory authorities have questioned the necessity and rationale for expanding production given the low overall capacity utilization and have requested further analysis of market demand for the new capacity [11][12]

Core Viewpoint - The vaccine industry is showing significant growth in the first three quarters of the year, with various vaccine types, including circular, diarrhea, brucellosis, and cat trivalent vaccines, continuing to perform well [1][2] Vaccine Batch Issuance - In the first three quarters, most vaccine types have seen substantial year-on-year growth, with specific increases in pig vaccines such as foot-and-mouth disease (+9.1%), circular vaccine (+29.5%), pseudorabies vaccine (+27.0%), and swine fever vaccine (+17.7%) [1] - Poultry vaccines like avian influenza trivalent vaccine (+9.6%) and Newcastle disease vaccine (+12.4%) also showed stable growth, while brucellosis vaccine experienced a remarkable increase of +60.2% [1][2] - Pet vaccines, particularly domestic rabies vaccine (+22.8%) and domestic cat trivalent vaccine (+74.4%), have maintained high growth rates [1] Factors Driving Growth - The growth in pig vaccines is attributed to multiple factors, including farming profitability, increased pig slaughter rates, and the introduction of new products [2] - The poultry vaccine sector continues to grow steadily, while the brucellosis vaccine benefits from the ongoing launch of new products [2] Veterinary Drug Raw Materials - As of October 22, the Veterinary Pharmaceutical Index (VPI) stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year [3] - The VPI index has shown a positive trend in October, with an average of 69.33, marking a 0.9% increase from September [3][4] Price Trends and Market Dynamics - The price of veterinary raw materials has been on the rise due to tightened supply and increased demand from large orders, particularly for products like tylosin [4] - The overall price increase in veterinary raw materials is driven by a combination of cost factors, corporate strategies, and market demand [4] Investment Recommendations - The industry is gradually recovering from a downturn, with a focus on undervalued companies that exhibit both elasticity and certainty [5] - Companies that have shown strong performance typically possess innovative qualities in product development, marketing strategies, or capital operations [6] - Recommended companies for investment include Ruipu Biological (300119.SZ), Kexin Biological (688526.SH), and others [6]

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting the industry index to outperform the benchmark index by over 5% in the next 3-6 months [81]. Core Insights - The animal health industry is gradually emerging from a low point, with a focus on undervalued companies that exhibit both elasticity and certainty. The report highlights that the ongoing internal competition has led to a market cleanup, with a recovery in the prices of veterinary raw materials and significant improvements in the year-on-year issuance of various vaccine types [70][71]. - The report emphasizes the importance of innovation in companies that have performed well, whether through product innovation, marketing strategies, or capital operations, which is reflected in their financial performance [70][71]. Summary by Sections Vaccine Issuance - In the first eight months of the year, most vaccine types showed significant year-on-year growth, particularly in swine vaccines such as foot-and-mouth disease vaccine (+11.0%), porcine reproductive and respiratory syndrome vaccine (+38.1%), and others. The report notes that the cat tri-vaccine saw a remarkable increase of +78.9% [10][11][9]. - The report indicates that the growth in vaccine issuance is driven by multiple factors, including the continued prosperity of farming, increased livestock inventory, disease outbreaks, and the introduction of new products [11][10]. Veterinary Raw Materials - As of September, the Veterinary Price Index (VPI) was reported at 69.22, reflecting a month-on-month increase of 2.0% and a year-on-year increase of 8.7%. This marks the first month-on-month increase after three consecutive months of decline [56][59]. - The report highlights that the price of various veterinary raw materials has improved, with significant increases in the prices of products like tiamulin and florfenicol, driven by supply constraints and increased demand [56][59]. Investment Recommendations - The report suggests focusing on companies that are undervalued yet possess strong growth potential, such as RuiPu Biological, KeQian Biological, and others. It notes that the competitive landscape is shifting, with larger companies outperforming smaller ones, indicating a potential for market consolidation in the future [70][71].

Core Viewpoint - The article highlights the significant growth and competitive advantages of Jinhe Biological, particularly in the veterinary pharmaceutical sector, driven by rising demand and pricing power in the livestock industry, as well as the burgeoning pet economy in China [1][5]. Group 1: Industry Trends - In the U.S., beef prices have reached historical highs, with ground beef prices increasing by 12% year-on-year in June. In China, the number of beef cattle decreased by 2.33% month-on-month in May, while calf prices surged by 26.37% year-on-year as of July 11 [1]. - The upward trend in calf prices and the decline in beef cattle inventory are expected to support beef prices in the latter half of 2025 and into 2026, indicating a sustained cycle of profitability in the beef industry [3]. Group 2: Company Performance - Jinhe Biological, a leader in the veterinary pharmaceutical market with a 50% global market share in oxytetracycline, has experienced rapid growth in performance this year, with a stock price increase of over 90% by April 10 [1][2]. - The company's net profit attributable to shareholders for the first half of 2025 increased by 51.52% year-on-year, reaching 138 million yuan, driven by increased sales of oxytetracycline and reduced raw material costs [2]. Group 3: Business Strategy and Growth Drivers - The company has established a dual-channel strategy in the pet health sector, with a focus on both imported and domestic brands, and has launched an AI-powered pet care app [4]. - The pet industry in China is projected to grow from 170.8 billion yuan in 2018 to 300.2 billion yuan by 2024, with a compound annual growth rate of 9.86% [4]. - Jinhe Biological's vaccine business is expected to see significant growth, particularly with the brucellosis vaccine, which has a market potential of around 4 billion yuan and could grow to 20 billion yuan due to increased demand and pricing [21]. Group 4: Competitive Advantages - The company benefits from scale advantages that drive cost reductions and efficiency improvements, with plans for a new factory expected to enhance profitability and reduce production costs [12]. - Jinhe Biological has established strong technical barriers and innovation capabilities, collaborating with research institutions to improve product quality and reduce impurities in its products [13][14]. - The company has a diversified business model that includes environmental protection and agricultural product processing, which contribute to stable performance [15]. Group 5: Future Outlook - The company aims to leverage its dual-drivers of pharmaceutical and vaccine segments to transition from a cyclical to a growth-oriented enterprise, indicating long-term investment value [28].

Financial Performance - The company achieved a revenue of 1.39 billion CNY in the first half of the year, representing a year-on-year growth of 30.45% [1] - The net profit attributable to shareholders reached 138 million CNY, with a year-on-year increase of 51.52% [1] - The adjusted net profit was 128 million CNY, reflecting a growth of 50.88% compared to the previous year [1] Segment Performance - The pharmaceutical segment saw significant growth, generating 860 million CNY in revenue, a 72.15% increase, accounting for 61.83% of total revenue [1] - The veterinary pharmaceutical segment reported improved sales and profit levels, with major products like the antibiotic premix showing substantial growth [2] Market Dynamics - The price of raw materials, such as corn, decreased by 11.90% compared to the previous year, contributing to lower production costs [2] - The U.S. pharmaceutical market has shown consistent growth, with increased sales of key products like the water-soluble antibiotic [2] - The domestic market for the antibiotic is expected to grow due to improved profitability in the pig farming sector and expanded sales channels [2] Product Development - The company has received approval for the antibiotic in targeted animals, particularly sheep, which is expected to contribute significantly to sales growth [3] - New products, including vaccines for various diseases, are anticipated to launch within the year, enhancing the product portfolio [2][3] Strategic Initiatives - The company is focusing on expanding its pet business, with 15 products currently available and more in the pipeline [2] - A new pet app, "Ai Pet Easy," is set to launch, incorporating AI features for enhanced user engagement and potential revenue generation [2][3] Challenges and Outlook - The solid waste landfill business experienced a temporary decline in revenue, but recovery is expected in the future [4] - The overall outlook for the pharmaceutical segment remains positive, with expectations of maintaining a relatively high gross margin [3]

Core Viewpoint - Jinhe Biotechnology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, achieving historical highs in both metrics, driven by strong sales in its veterinary pharmaceutical segment and a favorable cost environment [2][3]. Financial Performance - The company achieved operating revenue of 1.39 billion yuan, a year-on-year increase of 30.45% [2] - Net profit attributable to shareholders reached 138 million yuan, up 51.52% year-on-year [2] - Overall gross margin improved by 1.25 percentage points compared to the same period last year due to lower growth in operating costs relative to revenue growth [2] Business Segments - The veterinary pharmaceutical segment saw robust sales, particularly in the core product, Chlortetracycline, with both domestic and international markets experiencing growth [2][3] - The company has expanded its production capacity for Chlortetracycline to 61,000 tons per year, ensuring sufficient supply to meet future market demand [3] - The vaccine segment has established four major production bases in China and the U.S., with leading market shares in certain vaccine products [4] Market Expansion - The company is actively expanding its sales channels, resulting in increased market share and penetration for Chlortetracycline in the domestic market [3] - The U.S. market has shown a positive response to price increases, leading to further sales growth and market share expansion [3] - The pet care segment is being developed as a strategic focus, with a dual product line strategy in place [5]

Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in its veterinary pharmaceutical segment and a favorable cost environment [1] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.39 billion yuan, a year-on-year increase of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, reflecting a year-on-year growth of 51.52% [1] - The overall gross margin increased by 1.25 percentage points compared to the same period last year, due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Veterinary Pharmaceutical Segment - The sales of the veterinary chemical drug segment continued to perform well, with significant growth in both domestic and international markets, particularly for the main product, Chlortetracycline [1] - The company has established a diversified product structure centered around Chlortetracycline premix, which is widely used in livestock industries across various regions including China, the US, Canada, Europe, South America, Southeast Asia, India, and Vietnam [1] - The approval of Chlortetracycline premix for use in sheep by the Ministry of Agriculture and Rural Affairs in October 2024 has expanded its application scenarios [1] Group 3: Market Expansion and Innovation - The company has improved its domestic market share and penetration of Chlortetracycline through extensive channel expansion, with overseas markets also experiencing significant growth [2] - The vaccine segment has four production bases and two research centers, with 16 products currently on the market and over 20 in development or application stages [2] - The company’s differentiated and innovative products, such as the blue ear disease inactivated vaccine, have gained market recognition, with over 90% of the top 50 pig farming enterprises using its solutions [2] Group 4: Pet Health Business - Jinhe Biology is actively advancing its pet health business, focusing on chemical drugs and vaccines, with 15 products currently available and over ten products under application [3] - The pet health segment is positioned as a strategic priority for the company, with expectations for rapid growth in the veterinary vaccine sector, which is anticipated to become a significant driver of future revenue [3]

Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in the veterinary pharmaceutical sector, particularly in the overseas market [1] Group 1: Financial Performance - The company achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, marking a year-on-year increase of 51.52% [1] - The overall gross margin improved by 1.25 percentage points compared to the same period last year due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Product Performance and Market Expansion - The veterinary chemical drug segment saw continuous sales growth, with the main product, Chlortetracycline, experiencing increased sales in both domestic and international markets [2] - The company expanded its market share and penetration in the domestic market, particularly in the pig farming sector, which has seen improved profitability [2] - The overseas market also showed significant growth, with sales volume doubling in other export markets compared to the previous year [2] Group 3: Vaccine and Pet Business Development - The vaccine segment is gaining market recognition, with the blue ear disease inactivated vaccine achieving a leading market share domestically [2] - The company is actively advancing its pet health business, focusing on pharmaceutical and vaccine products, with plans to launch new products [3] - The veterinary vaccine segment is expected to become a high-growth area, potentially serving as a second growth curve for the company's performance [3]